47 results about "Plasma mhpg" patented technology

The invention relates to the field of medical informatics, and provides a diabetic nephropathy risk prediction method and system based on a protein marker. The method comprises the following steps: detecting the concentration of a protein marker in a plasma sample of a diabetic to obtain plasma protein marker concentration data; performing longitudinal correlation analysis on the protein markers according to the plasma protein marker concentration data to obtain the kidney disease related protein markers; performing feature screening on the kidney disease related protein marker combination to obtain a core protein marker; establishing a nephropathy risk prediction model through the clinical parameters of the diabetic patient and the core protein marker combination; and outputting a nephropathy risk prediction result of the patient to be detected through the nephropathy risk prediction model. The advanced intervention of the diabetic nephropathy is realized, and the prediction accuracy of the diabetic nephropathy is improved.

The utility model discloses a device for preparing platelet-rich plasma suspension and gel containing blood cells. Comprising a fixing frame, at least one rapid clamping pipe clamp installed on the fixing frame, a vacuum centrifugal pipe clamped in the rapid clamping pipe clamp, and two suction devices capable of being inserted into the centrifugal pipe from the top or the bottom of the centrifugal pipe. The pusher is used for pushing the aspirator to be inserted into the centrifugal tube; the rotating mechanism is used for driving the pusher to rotate so as to enable the aspirator to face the top or the bottom of the centrifugal tube; the utility model solves the problems of blood pollution, manual operation error and low extraction rate in the manual operation process in the prior art, retains all blood platelets and white blood cells in the blood, retains red blood cells in normal proportion and most plasma proteins, and improves the extraction efficiency. Moreover, the concentration of platelets and leukocytes is constantly about 4 times of the concentration of blood of common normal people, the functions of erythrocyte components are reserved, and the functional effects of various components in the blood can be better exerted.

The invention discloses an AKI, CKD and AKI-CKD progress general prediction model based on plasma proteomics and a construction method thereof. The construction method comprises the following steps: selecting a patient which has plasma proteomics data when a baseline which meets the inclusion standard of a research group, has eGFR greater than or equal to 60mL / min / 1.73 m < 2 > when the baseline exists, and has no AKI or CKD medical history; collecting clinical prediction factors and blood proteomics data of the modeling crowd; and randomly dividing the selected modeling crowd data into a training set and a verification set, screening out protein prediction markers such as protein WFDC2 and protein GDF15 shared with the development of the AKI, the CKD and the AKI-CKD, and establishing a general prediction model for the development of the AKI, the CKD and the AKI-CKD. Proteomics is used for predicting AKI-CKD progress for the first time, three renal function outcomes can be predicted at the same time, prediction indexes are simple and easy to obtain, and the model is a universal model with high prediction capacity.

The utility model provides a plasma protein separating and liquid adding device convenient to maintain, and relates to the technical field of biology, the plasma protein separating and liquid adding device convenient to maintain comprises a liquid adding rod body, the outer surface of the liquid adding rod body is fixedly connected with a mounting frame, and one end of the liquid adding rod body is provided with a buffer solution storage tank; a clamping assembly is arranged on the side face of the mounting frame and comprises a limiting sleeve, a fixing ring is fixedly connected to the inner wall of the limiting sleeve, a first elastic piece is fixedly connected to the side face of the fixing ring, a sliding ring is fixedly connected to the end, away from the fixing ring, of the first elastic piece, and a sleeve is fixedly connected to the side face of the limiting sleeve. A micro pump is arranged on the side face of the buffer solution storage tank, an adjusting valve is arranged at one end of the liquid adding rod body, during use, the liquid adding rod body is firstly pushed in along an inner cavity of the limiting sleeve, when the liquid adding rod body moves to a certain position, the side face of the mounting frame makes contact with the side face of the sliding ring, and therefore the first elastic piece can be promoted to be compressed.

The utility model provides a plasma protein chromatographic column storage rack which comprises a rack body, a storage table, a separation mechanism and a positioning mechanism, the storage table is erected on the rack body, the separation mechanism is arranged on the storage table, and the positioning mechanism is installed on the separation mechanism. The positioning mechanism comprises a first positioning block, a second positioning block and a sliding plate, the first positioning block and the second positioning block are L-shaped, a positioning groove is formed between the first positioning block and the second positioning block, the sliding plate can be inserted into the positioning groove and can also slide relative to the first positioning block and the second positioning block, and a lock catch assembly is further arranged on the sliding plate; the lock catch assembly is used for positioning the infusion tube on the sliding plate. According to the plasma protein chromatographic column storage rack, the infusion tubes cannot fall off from the positioning mechanism, and meanwhile, the infusion tubes can be locked on the partition plates so that the infusion tubes cannot be mutually wound to affect plasma transmission.

The present invention relates to compositions and methods for treating and / or preventing heart failure with preserved ejection fraction (HFpEF), especially in subjects with an impaired NO-cGMP-PKG signalling axis. The inventors established that not all patients with clinically defined HFpEF suffer from insufficient NO-cGMP-PKG signalling. In accordance with the invention, patients with an HFpEF diagnosis can be selected / stratified based on biomarkers such as NADPH oxidase Type 5 (Nox5) plasma levels, nitration of tyrosine residues on plasma proteins and / or cell-based assays. Moreover, the inventors have found that treating this signalling network at two or more nodes, especially sGC and NO synthase, achieves the first-in-class mechanism-based, causal and high precision therapy for HFpEF endotype which is defined by insufficient NO-cGMP-PKG signalling.

The invention relates to a blood shearing device and a blood compatibility evaluation method. The blood shearing device comprises an objective table, a fixing support, a supporting beam, a stator, a rotor and a driving source. The device can simultaneously adjust the roughness and wettability of the material surface, breaks through the limitation that only a single factor can be researched in the prior art, and provides a more comprehensive platform for systematically evaluating the blood compatibility; in the experimental method, red blood cell hemolysis is detected, and the degradation condition of plasma protein is evaluated synchronously, so that the overall injury mode of blood components under the action of an artificial surface can be reflected more truly. Experimental basis can be provided for material selection and surface optimization of blood contact type medical instruments such as an artificial heart pump, an ECMO and a hemodialysis machine, the clinical complication risk can be reduced, and development of artificial organs and blood purification technologies is promoted.

The present application relates to the field of medical informatics, and provide a paliperidone efficacy prediction method and system based on plasma proteomics, the method comprises the following steps: collecting the basic data of the target patient; selecting the protein features through the basic data to obtain the related proteins corresponding to the paliperidone efficacy; training the neural network based on the related proteins and the baseline data in the basic data to obtain the prediction model; predicting the paliperidone efficacy of the patient to be predicted through the prediction model to obtain the prediction result. The present application can predict the treatment response of schizophrenic patients to paliperidone, and significantly improve the objectivity of paliperidone use.

This invention discloses a plasma protein as a biomarker for diagnosing NSTEMI complicated with hypertension and its application. The characteristic is that the plasma protein biomarker is MYL3, which can be used in the preparation of products for diagnosing NSTEMI complicated with hypertension. The advantage is that it can diagnose NSTEMI complicated with hypertension at an early stage by measuring the plasma protein biomarker, providing an effective tool for the diagnosis of NSTEMI complicated with hypertension, with high detection efficiency and strong targeting.

The application discloses an axSpA diagnosis biomarker combination and application thereof in judging axSpA diagnosis effect, relates to the biomedical field, and comprises the following four plasma proteins: LIM and SH3 domain protein 1 (LASP1), calponin binding protein 2 (CNN2), neuron protein kinase C and tyrosine protein kinase substrate 2 (PACSIN2) and tropomyosin 4 (TPM4). The expression levels of the four proteins in the plasma of axSpA light / severe group patients are all up-regulated relative to a healthy control group, and there is a significant difference between the severe group and the light group. Through deep proteomics, multi-algorithm statistics, machine learning models and independent queue immunological verification, the protein combination composed of LASP1, CNN2, PACSIN2 and TPM4 is first systematically identified and verified as an excellent performance of axSpA diagnosis biomarker.

The present invention relates to a therapeutic composition from natural substances that targets cancer cells, specifically brain cancer cells, and to a method for preparing same, wherein the composition comprises: 1) a therapeutic agent extracted from black seed, in the form of thymoquinone and 2) between 238,671 and 1,500,000,000 platelets, wherein components (a) and (b) are dissolved in 1 mL blood plasma proteins.

The invention relates to a marker for detecting and / or diagnosing 21-trisomy syndrome, 18-trisomy syndrome and neural tube defects and application of the marker, and belongs to the technical field of medical detection. The marker provided by the invention is selected from one or more of maternal serum D-dimer (D-D), pregnancy related plasma protein A (PAPP-A) and free human chorionic gonadotropin beta subunit (Free beta-hCG). The D-D + PAPP-A + Free beta-hCG model provided by the invention has the highest diagnostic value for 21-trisomy syndrome (DS) and 18-trisomy syndrome (ES), and the combination of D-D and PAPP-A and / or Free beta-hCG can improve the diagnostic value, diagnostic sensitivity and screening effect for neural tube defects (NTD). A new marker and a screening scheme are provided for simultaneously monitoring and diagnosing DS, ES or NTD fetuses of early pregnancy pregnant women in the clinical early stage.

The invention belongs to the technical field of biological detection, and particularly relates to application of annexin A3 (ANXA3) in detection of critical illness death early warning and sepsis diagnosis. It is found that the ANXA3 protein amount in plasma of a critically ill patient is remarkably higher than that in a healthy voluntary person, the ANXA3 protein amount in plasma of a critically ill sepsis patient is remarkably higher than that in plasma of a critically ill non-sepsis patient, and the ANXA3 protein amount in the plasma is further remarkably related to the death risk of the critically ill patient. By detecting the blood plasma ANXA3 protein amount, sepsis occurrence and death risks of critically ill patients can be evaluated, individualized treatment can be started as soon as possible, and the kit has important clinical application value for prognosis of critically ill patients.

The invention discloses a biomarker for aortic dissection detection and an application of the biomarker. The biomarker is one or more of MDK, NTN1, CCL21, LIPC, DNASE1L3, TFPI2, CTSG, HAMP, CXCL14, PLA2G2A, SCUBE1, GZMK, HP1BP3, SRP14 and TOP1. The biomarker is obtained by screening plasma of a patient with aortic dissection through plasma proteomics, and shows relatively high sensitivity and specificity. ELISA verification proves that the biomarker can be used as an early diagnostic biomarker of the aortic dissection, and can also be used as one of indexes for evaluating the disease severity of AD patients, so that a new direction is provided for clinical early diagnosis and long-term prognosis evaluation of the aortic dissection.

The invention provides a system for predicting the level of pulmonary artery systolic pressure after sudden plateau entry, and the system obtains the plasma protein marker content, nicotinamide phosphoribosyltransferase, HECT structural domain E3 ubiquitin protein ligase 3 and heat shock protein family A member 1A of a testee in a plain area to predict the level of pulmonary artery systolic pressure 7 days after sudden plateau entry. And acquiring the plasma protein marker content and synaptic binding protein II of the testee 7 days after the testee rapidly enters the plateau to predict the pulmonary artery systolic pressure level 1 year after entering the plateau. The method can predict the pulmonary artery systolic pressure grade of the subject after the subject enters the plateau or enters the plateau for one year according to the plasma protein marker content of the subject, and is used for screening susceptible people in an early stage.

This invention relates to bifunctional compounds and the use of such bifunctional compounds to reduce plasma levels of extracellular target molecules via lysosomal degradation. These bifunctional compounds have cell surface receptor ligands covalently linked to ligands capable of binding to extracellular target molecules (such as growth factors, cytokines, chemokines, hormones, neurotransmitters, capsids, soluble receptors, extracellular secretory proteins, antibodies, lipoproteins, exosomes, viruses, cell or plasma membrane proteins), wherein said cell surface receptors are associated with receptor-mediated endocytosis, including lysosomal degradation mediated by desialylate glycoprotein receptor (ASGPR) and lysosomal degradation mediated by mannose-6-phosphate receptor (M6PR). Pharmaceutical compositions comprising such bifunctional compounds and methods of treating diseases or disorders mediated by extracellular molecules using such bifunctional compounds are also provided herein.

This application relates to the field of medical testing technology, specifically to a biomarker, diagnostic method, and application for the diagnosis of liver fibrosis. Through plasma proteomics analysis of patients with liver fibrosis, this application has discovered and validated a series of biomarkers and combinations thereof with clinical value for the early diagnosis of liver fibrosis.

The present application belongs to the technical field of blood product preparation, and particularly relates to a method for separating blood coagulation factor VIII and vWF factor from blood plasma. The method comprises the following steps in sequence: after cellulose is balanced, the cellulose is mixed with raw material blood plasma, filtered after stirring, and cellulose precipitate is obtained; after the cellulose precipitate is eluted, the cellulose precipitate is soaked in precipitate dissolving solution, and filtrate is obtained by filtering; the filtrate is subjected to three times of ion exchange chromatography, and factor VIII and / or vWF factor product is obtained. The technical scheme solves the technical problems of the prior art, such as complicated process steps for purifying and enriching human blood coagulation factor VIII and vWF from blood plasma cold precipitate, and unsatisfactory production efficiency and product quality. The cold precipitate protein solution prepared by the method can separate factor VIII, vWF factor and fibrinogen product at the same time through chromatography, improve the utilization rate of plasma protein, and has an ideal application prospect.

The invention discloses a < 19 > F MRI (Magnetic Resonance Imaging) composite nano contrast agent based on a targeting artificial protein crown as well as a preparation method and application thereof. According to the invention, folic acid is modified on plasma protein, and the modified plasma protein has folic acid receptor mediated specific targeting and selective tumor cell uptake by utilizing the overexpression characteristic of a folic acid receptor (FR) on the surface of a cancer cell. Meanwhile, by taking 20-fluoro-15-crown-5-ether as a magnetic resonance active molecule, packaging by using polylactic acid-glycolic acid, and synthesizing PLGA-PFCE nano-particles as the < 19 > F MRI nano contrast agent. The PLGA-PFCE nanoparticles and the modified plasma protein are co-incubated in vitro, an artificial protein crown is formed on the surface of the PLGA-PFCE nanoparticles, and the obtained 1PLGA-PFCE nanoparticle-targeting artificial protein crown compound directly realizes targeting to tumors through targeting small molecules on the surface of the protein crown; moreover, the characteristic that the targeting effect is reduced due to the fact that a common nano material adsorbs a protein crown after entering a living body can be overcome, and the signal intensity of < 19 > F MRI tumor in-situ imaging can be improved after the nano material is enriched to the tumor through intravenous injection.

The invention discloses a plasma protein tubular membrane concentration device and a plasma protein tubular membrane concentration process, and relates to the technical field of plasma protein concentration process.The plasma protein tubular membrane concentration device comprises a plasma storage tank, a first liquid outlet pipe is installed at the bottom of the plasma storage tank, and a first feeding pump is installed at the bottom of the first liquid outlet pipe; a first liquid inlet pipe is sequentially installed on the first feeding pump, a centrifugal tank is installed on one side of the outer portion of the plasma storage tank, the first liquid inlet pipe is connected with the top of the centrifugal tank, a second liquid outlet pipe is installed on the lower portion of one side of the centrifugal tank, and a second feeding pump is installed on the other side of the second liquid outlet pipe. A second liquid inlet pipe is installed at the top of the second feeding pump, and a stirring tank is installed on one side of the outer portion of the centrifugal tank. According to the scheme, the problems that an existing plasma protein tubular membrane concentration device does not have the cleaning function in the using process, and a membrane element flow channel in membrane equipment is prone to being blocked are solved.

The application discloses a method for determining the bismuth plasma protein binding rate of bismuth potassium citrate, and is characterized in that the method comprises plasma sample pretreatment and sample determination. The determination method can solve the stability problem of bismuth potassium citrate in plasma, can make protein binding more sufficient, can effectively promote the dissociation of bismuth and plasma protein, can make the detected protein binding rate closer to the real value, has great significance for guiding clinical medication, is simple and easy to operate, can realize rapid detection, and has low dependence on instruments.

The invention discloses a method for constructing a model for accurately predicting meningeal metastasis risk of non-small cell lung cancer based on plasma protein and application, and relates to the technical field of biological medicine. Aiming at the problems of late discovery and difficult diagnosis of NSCLC-LM, the inventor tries to adopt an Olink proteomics technology for the first time to know whether an LM risk exists or not in advance by detecting specific plasma protein of a patient in a relatively non-invasive manner, so that the patient is helped to find and treat early. Therefore, the inventor firstly collects blood samples of LM and nLM patients, then constructs a risk prediction model by using a training set, and finally judges the efficiency of the model through a verification set. A result shows that five specific proteins, namely FGF2, CD4, IL15, CXCL12 and PDCD1LG2, participate in model construction, the area under a queue curve is 0.8 or above, and the sensitivity and the specificity both reach relatively high levels. The invention has great significance in the fields of early diagnosis and screening of NSCLC-LM and the like.

The invention belongs to the technical field of plasma protein markers, and discloses a plasma protein marker and a risk prediction system for a heart failure onset risk of a type 2 diabetes mellitus patient, and the protein marker combination is applied to preparation of a kit for predicting the heart failure onset risk of the type 2 diabetes mellitus patient. The protein marker combination comprises a C-C motif chemotactic factor 24, a C-C motif chemotactic factor 7, a carcino-embryonic antigen related cell adhesion molecule 6, a fiber gelling protein 1, a follistatin, a polypeptide N-acetylgalactosamino transferase 5, an ADP ribosylation factor binding protein GGA1, a kallikrein 4, a nerve bundle protein, renin, a plasma protease C1 inhibitor and cardiac troponin I, the brain natriuretic peptide comprises a brain natriuretic peptide precursor, an N-terminal brain natriuretic peptide precursor, apolipoprotein C1, tetramer connexin, a Mepin A beta subunit and multi-ligand proteoglycan-4. The invention further constructs a risk score and prediction model for predicting the attack risk of the heart failure of the type 2 diabetes mellitus patient based on the protein marker.

The invention relates to the technical field of medical detection, in particular to a liver fat quantitative evaluation method and system based on plasma proteomics. The method comprises the following steps: acquiring a plasma sample of an individual; acquiring a plasma protein level according to the plasma sample; combining a proton density fat fraction of magnetic resonance imaging to obtain an influence weight of the fat content of the liver; establishing a liver fat content prediction model; and realizing quantitative evaluation of the liver fat content through the liver fat content prediction model. According to the invention, non-invasive liver fat detection is realized through plasma proteomics analysis, and a specific marker group is screened out; a liver fat content prediction model is constructed by using 10 / 62 plasma protein levels, so that the risk of fatty liver occurrence of an individual is evaluated more accurately; through clinical verification, the marker and the algorithm are optimized, so that the detection specificity and reliability are ensured; a rapid detection kit is developed, so that the cost is greatly reduced, and the accessibility of a medical institution is improved.

This invention discloses a method and apparatus for solute removal in hemodialysis with precise membrane pore size control, belonging to the field of blood purification technology. The method involves introducing blood and dialysate into both sides of a dynamically controlled bilayer heterostructure dialysis membrane, collecting characteristic signals of metabolic solutes and plasma functional proteins in the blood, inputting these signals into an adaptive pore size decision model, and outputting target pore size and electric field strength parameters. A low-frequency alternating electric field drives reversible conformational changes in stimulus-responsive polymer chains within the membrane, achieving precise control of the membrane channel's effective sieving pore size, locking the pore size within a threshold range where small molecule solutes permeate while plasma functional proteins are completely retained. Combining axial gradient channels and radial charge sieving mechanisms within the membrane achieves graded and targeted solute removal. A piezoelectrically driven periodic micro-pulsating flow field removes the fouling layer from the membrane surface, improving mass transfer stability. This invention automates and precisely controls the dialysis process, improving solute removal efficiency and plasma protein protection.

The invention belongs to the technical field of biological medicine, and particularly discloses a multi-protein marker combination for intervertebral disc degeneration prediction and severity evaluation and a machine learning algorithm. The marker combination comprises any three or more of COL6 [alpha] 3, REG1beta, ATF5, CAP1, MAGEA4 and LILRB3, and preferably six proteins are combined for use. And quantitatively detecting the expression level of the protein in the blood plasma through enzyme-linked immunosorbent assay (ELISA), constructing a prediction model in combination with a binary Logistic regression algorithm, and outputting an intervertebral disc degeneration grading result. Experiments show that the AUC (area under curve) of joint detection of six proteins reaches 0.870, which is averagely improved by 11.8% compared with that of single protein detection, and the AUC is obviously superior to that of an existing imaging grading method. According to the present invention, the intervertebral disc degeneration plasma protein diagnosis system is established based on the SOMAscan technology for the first time, the protein concentration threshold of the ELISA verification is provided, the efficient complementation with the MRI Pfirrmann grading is achieved, the advantages of noninvasive property, objective property and high sensitivity are provided, and the new method is provided for the clinical early screening and dynamic monitoring.

The invention discloses a group of plasma protein markers and application thereof in an ovarian cancer early diagnosis kit. Uniprot codes of the markers are respectively P02042, P02741, P02776, P06727, P07451, P07738, P30043, P68871, P69905, Q13228 and Q8IUL8, and the corresponding coding genes are respectively HBD (Hepatitis B Virus), CRP (C-Reactive Protein), PF4, APOA4, CA3, BPGM (Brassica Peptide), BLVRB (Brassica Peptide), BLVRB (Brassica Peptide Virus), HBB (Hepatitis B), HBA1, SELENBP1 and CILP2. According to the invention, a mathematical model for ovarian cancer diagnosis is constructed, the AUC under a subject ROC curve in external verification reaches 0.96, and the accuracy reaches 0.89. The protein molecular marker provided by the invention has good diagnostic index characteristics, can be effectively used for early diagnosis of ovarian cancer, and has high clinical use and popularization values.

The application discloses a method for constructing a precise prediction non-small cell lung cancer meningeal metastasis risk model based on plasma proteins and application, and relates to the technical field of biological medicine. In view of the problems of NSCLC-LM late discovery and difficult diagnosis, the inventors first attempt to use Olink proteomics technology to detect specific plasma proteins of patients in a relatively non-invasive way to know whether there is a LM risk in advance, and help patients to discover and treat early. For this purpose, the inventors first collect blood samples of LM and nLM patients, then use the training set to construct a risk prediction model, and finally judge the model performance through the validation set. The results show that FGF2, CD4, IL15, CXCL12 and PDCD1LG2 5 specific proteins are involved in model construction, and the area under the curve of the cohort is above 0.8, and the sensitivity and specificity also reach a high level. The application has great significance in the field of early diagnosis and screening of NSCLC-LM.

The application belongs to the technical field of proteomics and clinical disease screening, and relates to application of a combination of plasma proteins in screening of pancreatic cancer. The application is based on mass spectrometry quantitative proteomics technology, screens and determines a marker combination composed of four plasma proteins of GCLC, ALAD, HAGH and SORD, and comprehensively analyzes relative abundance of the marker combination through a binary Logistic regression model to distinguish pancreatic cancer patients from healthy people. Experimental results show that the protein combination has high sensitivity, specificity and area under curve (AUC) in a screening set and an independent verification set, and has good stability and repeatability. The method has the advantages of non-invasiveness, feasible operation and applicability to population screening by taking plasma as a detection sample, and can provide a new technical means for early screening of pancreatic cancer.

This invention discloses a method and device for predicting disease risk based on plasma proteomics and waist circumference, belonging to the field of medical data processing. Utilizing 2,920 plasma proteins from 52,879 participants in the UK Biobank, this invention constructs a proteomics-based waist circumference proWC score using LASSO regression, and derives the protein-anthropometric difference index proWCΔ to quantify the difference between proteomics-based waist circumference and measured waist circumference. Based on the proWC score and proWCΔ, disease risk association analysis, mortality prediction, causal mediation analysis, and dietary association analysis were conducted across 14 organ systems, demonstrating that proWC has superior clinical predictive value compared to waist circumference alone. Furthermore, based on proWC, a hidden high-risk subgroup was identified—patients with normal measured waist circumference but a near-overtly obese risk of diabetes-related death. By constructing proWCΔ and proWC, this invention elevates the assessment of central obesity from morphological measurements to the molecular level, providing a new molecular framework for precise risk stratification of central obesity.